These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22536370)

  • 1. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    Lovly CM; Dahlman KB; Fohn LE; Su Z; Dias-Santagata D; Hicks DJ; Hucks D; Berry E; Terry C; Duke M; Su Y; Sobolik-Delmaire T; Richmond A; Kelley MC; Vnencak-Jones CL; Iafrate AJ; Sosman J; Pao W
    PLoS One; 2012; 7(4):e35309. PubMed ID: 22536370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Tomić I; Pavić M
    Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
    Tseng D; Kim J; Warrick A; Nelson D; Pukay M; Beadling C; Heinrich M; Selim MA; Corless CL; Nelson K
    J Am Acad Dermatol; 2014 Aug; 71(2):229-36. PubMed ID: 24842760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.
    Ponti G; Pellacani G; Tomasi A; Loschi P; Luppi G; Gelsomino F; Longo C
    Dis Markers; 2014; 2014():671283. PubMed ID: 24591764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
    Varada S; Mahalingam M
    Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.
    Taskin OC; Sari SO; Yilmaz I; Hurdogan O; Keskin M; Buyukbabani N; Gulluoglu M
    Turk Patoloji Derg; 2023; 39(1):23-30. PubMed ID: 35642348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
    Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
    Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Translational research and diagnostics of melanoma].
    Rüschoff J; Kleinschmidt M; Middel P
    Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational profiling of acral melanomas in Korean populations.
    Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
    Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
    Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
    J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
    Lee SH; Kim JE; Jang HS; Park KH; Oh BH; Shin SJ; Chung KY; Roh MR; Rha SY
    Cancer Res Treat; 2018 Oct; 50(4):1378-1387. PubMed ID: 29361821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
    Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.